1. Introduction {#s0005}
===============

An increasing number of cell types have been shown to shed microvesicles (MVs) under both physiological and pathological conditions. MVs have been demonstrated to contain a wide array of biological effector molecules, including proteins, lipids, DNA, microRNA and mRNA, and since MVs can interact with other cells, they can serve as a means of cell-to-cell communication ([@bb0135]). MVs can interact with other cells either through direct membrane fusion, or by utilising adhesion molecules such as L1 ([@bb0075]) and CD44 ([@bb0270]), or signalling molecules such as integrins ([@bb0040; @bb0195]) located on the MV surface. MVs can initiate various biological events in target cells, ranging from apoptosis ([@bb0030; @bb0260]) to cell survival and proliferation ([@bb0245; @bb0265]). They have also been shown to mediate horizontal mRNA transfer ([@bb0245; @bb0265]).

Fibroblasts ([@bb0120]), reticulocytes ([@bb0100]), endothelial cells ([@bb0195]), lymphocytes ([@bb0175]), dendritic cells ([@bb0235]) and platelets ([@bb0085]), as well as by numerous cancer cell types ([@bb0065; @bb0040]) have been shown to shed MVs. The MV population can be subdivided into exosomes and shedding vesicles based on their size and origin. Exosomes are 40--100 nm in diameter and are derived from endosomal multivesicular bodies ([@bb0200]), while shedding vesicles are 100--1000 nm in diameter and are generated by outward budding of the plasma membrane ([@bb0025]). Cells commonly release both exosomes and shedding vesicles into the extracellular space, with this mixed population referred to as 'microvesicles' (MVs).

MVs shed by tumour cells contain tumour antigens and can thus contribute to immune system evasion ([@bb0240]). Tumour MVs may also contribute to tumour invasion, as they contain proteinases that degrade the ECM. For example, MVs have been demonstrated to contain cathepsin B ([@bb0070]), matrix metalloproteinase (MMP)-2 ([@bb0065]), MMP-9 ([@bb0065; @bb0040]), MT1-MMP ([@bb0195]), and urokinase-type plasminogen activator ([@bb0065]), as well as the adamalysins ADAM10 ([@bb0075; @bb0270]) and ADAM17 ([@bb0270]).

We have previously shown that G26/24 oligodendroglioma cells shed MVs, which contain Fas ligand and tumour necrosis factor α-related apoptosis-inducing ligand and induce apoptosis in neurons and astrocytes ([@bb0030; @bb0260]). In addition to their effects on healthy cells within the brain, oligodendrogliomas remodel the brain extracellular matrix (ECM) and invade into surrounding tissues ([@bb0010]). Along with other lecticans, aggrecan is a constituent of the brain ECM ([@bb0225; @bb0010]). In particular, aggrecan is thought to be an important component of perineuronal nets ([@bb0140]), with its expression altered in pathological conditions such as Alzheimer\'s disease ([@bb0155]) and early-life seizure ([@bb0145]).

Aggrecan is also a major constituent of the ECM of cartilage, and aggrecan degradation is associated with progression of various types of arthritis ([@bb0130]). During the development of rheumatoid arthritis (RA), the cartilage matrix is invaded by fibroblasts originating from the synovial lining ([@bb0170]). The invading synovial cells have been shown to express a number of ECM-degrading MMPs ([@bb0160]) as well as metalloproteinases with disintegrin and thrombospondin motifs (ADAMTSs) ([@bb0230]). ADAMTS-4 and ADAMTS-5 are thought to be the primary 'aggrecanases' responsible for aggrecan degradation in osteoarthritis ([@bb0160]).

Our results demonstrate for the first time that MVs shed by both oligodendroglioma cells and rheumatoid synovial fibroblasts contain a TIMP-3-sensitive aggrecanase activity. This suggests that MVs may contribute to cellular invasion of aggrecan-rich extracellular matrices.

2. Results {#s0010}
==========

2.1. G26/26 MVs cleave aggrecan at several sites {#s0015}
------------------------------------------------

Using a panel of antibodies that recognise aggrecan degradation products, we found that MVs shed by G26/24 oligodendroglioma cells are able to degrade aggrecan at several sites.

Following incubation of 500 nM aggrecan with MVs (4 μg protein) for 24 h at 37 °C, aggrecan degradation was visible using the 2-B-6 antibody ([@bb0020]), which recognises chondroitinase-treated aggrecan fragments ([Fig. 1](#f0005){ref-type="fig"}A). The pattern of the fragments generated by 4 μg of G26/24 MVs mirrored that obtained after incubation of aggrecan with 0.01 nM of recombinant ADAMTS-5.

Aggrecan degradation by G26/24 MVs was further investigated using a panel of neoepitope antibodies that recognise aggrecan cleavage at sites previously shown to be hydrolysed by ADAMTS-4 and ADAMTS-5 ([@bb0105; @bb0255; @bb0205]). Following 24 h of incubation at 37 °C with 4 μg of MVs, aggrecan degradation was visible using anti-^1772^AGEG and anti-GELE^1480^ antibodies, indicating that MVs cleaved aggrecan at the TAQE^1771^--^1772^AGEG and GELE^1480^--^1481^GRGT sites in the chondroitin sulfate-rich region ([Fig. 1](#f0005){ref-type="fig"}A). The aggrecanase activity of MVs was the same whether 0.05% Brij 35 was included in the assay buffer or not. The degradation products were comparable with those generated by incubation of aggrecan with 0.01 nM recombinant ADAMTS-5 ([Fig. 1](#f0005){ref-type="fig"}A).

MV cleavage of aggrecan at the NITEGE^373^--^374^ARGSV site in the interglobular domain was not detectable with an anti-^374^ARGSV neoepitope antibody ([@bb0095]) following incubation of 500 nM aggrecan with 4 μg of MVs for 24 h at 37 °C ([Fig. 1](#f0005){ref-type="fig"}A). Incubation of aggrecan with recombinant ADAMTS-5 (5 nM) generated the expected cleavage product.

Aggrecan degradation by G26/24 MVs was shown to be time- and dose-dependent. Using the anti-^1772^AGEG antibody, degradation of aggrecan by 2 μg of MVs was linear for up to 4 h ([Fig. 1](#f0005){ref-type="fig"}B). Aggrecan degradation was also dose-dependent, with formation of the ^1772^AGEG neoepitope increasing linearly over 3 h for 0.1 to 10 μg of MVs ([Fig. 1](#f0005){ref-type="fig"}C).

2.2. G26/26 MV aggrecan-degrading activity is inhibited by TIMP-3 {#s0020}
-----------------------------------------------------------------

We investigated the inhibitor sensitivity of the aggrecan-degrading activity of G26/24 MVs by incubating MVs with various proteinase inhibitors and measuring residual activity against the TAQE^1771^--^1772^AGEG site.

The metal chelator EDTA (10 mM) blocked the formation of the ^1772^AGEG neoepitope, indicating that a metalloproteinase is responsible for degradation ([Fig. 2](#f0010){ref-type="fig"}). GM6001, a hydroxamate metalloproteinase inhibitor, also inhibited aggrecan cleavage by G26/24 MV, with GM6001 inhibiting activity completely at 100 μM and partially at 10 μM ([Fig. 2](#f0010){ref-type="fig"}).

TIMP-1 and TIMP-2 (100 nM) had no effect on aggrecan degradation by G26/24 MV, while N-TIMP-inhibited activity strongly and similarly to N-TIMP-3 inhibition of ADAMTS-5. This inhibitory profile indicates that an ADAMTS or related TIMP-3-sensitive metalloproteinase is responsible for the observed aggrecanase activity.

2.3. G26/26 cells express aggrecanolytic ADAMTSs {#s0025}
------------------------------------------------

RT-PCR confirmed the expression of *Adamts1*, *Adamts4* and *Adamts5* by G26/24 cells ([Fig. 3](#f0015){ref-type="fig"}).

2.4. Rheumatoid synovial fibroblast MVs cleave aggrecan in a TIMP-3-sensitive manner {#s0030}
------------------------------------------------------------------------------------

To investigate whether other cell types also shed MVs containing aggrecan-degrading activity, we isolated MVs shed by primary rheumatoid synovial fibroblasts, normal skin fibroblasts and HTB94 chondrosarcoma. The RA synovial fibroblast MVs (4 μg of protein) cleaved aggrecan at the TAQE^1771^--^1772^AGEG bond, while no activity was detected with normal skin fibroblast or HTB94 MVs (4 μg) ([Fig. 4](#f0020){ref-type="fig"}A). Aggrecan degradation by RA fibroblast MVs was inhibited by 100 nM TIMP-3, indicating that this activity is also likely to be due to an ADAMTS or related metalloproteinase.

3. Discussion {#s0035}
=============

To our knowledge, this is the first description of aggrecanase activity being present in microvesicles shed from two different cell types: oligodendroglioma and rheumatoid synovial fibroblasts. Based on our inhibitor studies, the aggrecanase activity in the shed MVs is likely to be due to ADAMTS metalloproteinase(s). ADAMTS-1, -4, -5, -8, -9, 15, -16 and -18 have all been reported to degrade aggrecan ([@bb0160]). Among these, ADAMTS-1 ([@bb0115]), ADAMTS-4 ([@bb0105]) and ADAMTS-5 ([@bb0255]) are the best characterised to date and show the strongest aggrecanase activity. By RT-PCR, we confirmed that G26/24 oligodendroglioma cells express all three of these enzymes, as previously shown for glioblastomas ([@bb0090]). RA synovial fibroblasts are known to express ADAMTS-4 and ADAMTS-5 ([@bb0230]). These enzymes are thus candidates for the aggrecanase activity observed in the MVs. The MVs may contain a number of ADAMTSs, including those whose expression has been confirmed as well as others that remain to be characterised. We were unable to identify ADAMTSs present in the MVs by immunohistochemistry due to the insensitivity of currently available antibodies. This limitation, coupled with the low level at which the enzymes are expressed in tissues, has hampered direct detection of aggrecanases in various tissue samples.

G26/24 MVs cleaved aggrecan at two sites in the chondroitin sulfate-rich region, namely at the TAQE^1771^--^1772^AGEG and GELE^1480^--^1481^GRGT bonds. However, no cleavage of aggrecan at the characteristic NITEGE^373^--^374^ARGSV aggrecanase site in the interglobular region was detected. This may be because higher concentrations of enzyme are required to detect cleavage at the NITEGE^373^--^374^ARGSV site than at the TAQE^1771^--^1772^AGEG and GELE^1480^--^1481^GRGT sites. For example, 5 nM recombinant ADAMTS-5 was required to detect aggrecan cleavage using the anti-^374^ARGSV antibody, while 0.01 nM ADAMTS-5 was sufficient to detect cleavage using the anti-^1772^AGEG and anti-GELE^1480^ antibodies, in line with previous findings ([@bb0255]). We found that 4 μg of MVs from G26/26 cells cleaved aggrecan comparably to 0.01 nM ADAMTS-5 at the TAQE^1771^--^1772^AGEG and GELE^1480^--^1481^GRGT sites, suggesting that 2000 μg of MVs would be required to detect activity at NITEGE^373^--^374^ARGSV. We were not able to isolate sufficient amounts of MVs to test this hypothesis.

Furthermore, we have found that heparin inhibits ADAMTS-4 hydrolysis of aggrecan, and that hydrolysis of the NITEGE^373^--^374^ARGSV site is more sensitive to inhibition by heparin than the GELE^1480^--^1481^GRGT site ([@bb0050]). Our data may thus indicate that the aggrecan-degrading activity in G26/24 MVs has similar properties and is associated with a heparan sulfate proteoglycan on the surface of MVs. Membrane-associated aggrecanase activity was first described by Billington et al. in preparations of bovine nasal chondrocyte membranes ([@bb0015]). ADAMTS-4 is thought to associate with syndecan 1 on the surface of chondrosarcoma cells ([@bb0250]), and ADAMTS-5 to associate with syndecan 4 on chondrocytes ([@bb0045]). We thus postulate that the aggrecanase activity is associated with the surface of the MVs through interaction with heparan sulfate proteoglycans.

Both oligodendroglioma and rheumatoid synovial fibroblasts are capable of invading into brain and cartilage extracellular matrices, which are rich in lectican chondroitin sulfate proteoglycans such as aggrecan, versican, brevican and neurocan. Our findings suggest that shed MVs may contribute to the ECM-degrading and invasive capacity of the cells. Degradation of brevican by ADAMTSs has been shown to generate a cleaved fragment that increases the invasiveness of glioma cells ([@bb0165]), suggesting that aggrecanase activity in shed MVs may also indirectly increase invasive capacity. The presence of ADAMTSs in shed MVs may represent a novel mechanism by which cells target these enzymes to lectican substrates in diverse extracellular matrices.

4. Experimental procedures {#s0040}
==========================

4.1. Materials {#s0045}
--------------

Human ADAMTS-5 lacking the C-terminal thrombospondin domain ([@bb0255]), bovine aggrecan ([@bb0080]), TIMP-1 ([@bb0215]), TIMP-2 ([@bb0215]), TIMP-3 ([@bb0275]) and N-TIMP-3 ([@bb0110]) were prepared as previously described. GM6001 was from Elastin Products (Owensville, USA).

4.2. Cell culture {#s0050}
-----------------

Murine G26/24 oligodendroglioma and human HTB94 chondrosarcoma cells were maintained in DMEM supplemented with 10% foetal calf serum, and 1% penicillin/streptomycin. Human synovial fibroblasts were obtained with ethics approval and informed consent from synovial tissue of RA patients undergoing joint replacement surgery as previously described ([@bb0150]). Normal human skin fibroblasts were obtained with ethics approval and informed consent from patients undergoing surgery for Dupuytren\'s disease as previously described ([@bb0220]).

4.3. Preparation of MVs from conditioned medium {#s0055}
-----------------------------------------------

MVs were prepared from media conditioned for 24 h on subconfluent cells. Media were centrifuged at 2000 *g* (15 min, 4 °C) and 4000 *g* (15 min, 4 °C) to remove debris. MVs were collected from the supernatant by centrifugation at 105 000 *g* (90 min, 4 °C) and re-suspended in phosphate-buffered saline, pH 7.5. MVs were quantified based on protein content using the Bradford assay (Protein Assay Reagent, Bio-Rad, UK) with BSA as a standard protein.

4.4. Aggrecanase assay {#s0060}
----------------------

Aggrecan (500 nM, 50 μg in 50 μl assay volume) was incubated with MVs or ADAMTS-5 in 50 mM Tris--HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl~2~, and 0.05% Brij 35 at 37 °C. For inhibitor analysis, ADAMTSs or MVs were pre-incubated with inhibitors (1 h, 37 °C) before addition of aggrecan. Samples were prepared for immunoblotting by treatment with chondroitinase ABC and keratanase (Seikagaku, Japan) (0.01 units each, 16 h, 37 °C) and precipitation with acetone (5 volumes, − 20 °C, 18 h). Degradation was visualised using antibodies recognising degraded aggrecan fragments as before ([@bb0205]). The 2-B-6 antibody recognises chondroitinase-treated aggrecan ([@bb0020]); anti-^374^ARGSV recognises aggrecan cleaved at NITEGE^373^--^374^ARGSV ([@bb0095]), anti-GELE^1480^ recognises aggrecan cleaved at GELE^1480^--^1481^GRGT ([@bb0105]) and anti-^1772^AGEG recognises aggrecan cleaved at TAQE^1771^--^1772^AGEG ([@bb0205]). Blots were quantified using ImageJ software.

4.5. RT-PCR {#s0065}
-----------

*Adamts* expression was evaluated by RT-PCR of the total RNA extracted from G26/24 and mouse embryonic fibroblasts (MEF) using a QIAamp RNA Blood Mini Kit (Qiagen Ltd, UK). Primers for *Adamts1* amplification were: 5′-CAGGAAGCATAAGGAAGAAG-3′ (forward) and 5′-GCACAGTGCTTAGCATCATCA-3′ (reverse), for *Adamts4*: 5′-ATGTGGGCACAGTGTGTGAT-3′ (forward) and 5′-CAAGGTGAGTGCTTCGTCTG-3′ (reverse), and for *Adamts5*: 5′-GGCATCATTCATGTGACACC-3′ (forward) and 5′-CGAGTACTCAGGCCCAAATG-3′ (reverse) ([@bb0185]).
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![G26/24 MVs degrade aggrecan. (A) Aggrecan was incubated alone (−), or with recombinant ADAMTS-5 (5 nM for detection with anti-^374^ARGSV, 0.01 nM for all other antibodies), or G26/24 MVs (4 μg) for 24 h at 37 °C and degradation products analysed by immunoblotting with the indicated antibodies. (B) Aggrecan was incubated with G26/24 MVs (2 μg) at 37 °C for various times and formation of the ^1772^AGEG neo-epitope visualised by immunoblotting. (C) Aggrecan was incubated with G26/24 MVs (0.1--10 μg, 3 h, 37 °C) and formation of the ^1772^AGEG neo-epitope visualised by immunoblotting.](gr1){#f0005}

![Aggrecan degradation by G26/24 MVs is due to a TIMP-3-sensitive metalloproteinase. G26/24 MVs (4 μg) or ADAMTS-5 (0.001 nM) were incubated alone (−) or with EDTA (10 mM), TIMP-1 (100 nM), TIMP-2 (100 nM), GM6001 (5--100 μM) or N-TIMP-3 (5--100 nM) (1 h, 37 °C). Residual activity against aggrecan (3 h, 37 °C) was visualised using the anti-^1772^AGEG neo-epitope antibody.](gr2){#f0010}

![G26/24 cells express ADAMTS-1, ADAMTS-4 and ADAMTS-5. RT-PCR for *Adamts1*, *Adamt4* and *Adamts5* was performed on total RNA isolated from G26/24 cells and MEF cells. Negative controls were performed without template.](gr3){#f0015}

![RA synovial fibroblast MVs degrade aggrecan. (A) Aggrecan was incubated alone (−) or with MVs from G26/24 (4 or 1 μg), normal skin fibroblasts (4 μg), RA synovial fibroblasts (4 μg) or HTB94 chondrosarcoma (4 μg) (24 h, 37 °C). Degradation products were analysed by immunoblotting using an anti-^1772^AGEG neo-epitope antibody. (B) MVs from G26/24 (4 μg) or RA synovial fibroblasts (4 μg) were pre-incubated with TIMP-3 (0--100 nM, 1 h, 37 °C) and residual activity against aggrecan (24 h, 37 °C) visualised using an anti-^1772^AGEG neo-epitope antibody.](gr4){#f0020}
